Sana Biotechnology (NASDAQ:SANA) Lowered to “Sell” Rating by Wall Street Zen

Sana Biotechnology (NASDAQ:SANA) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Monday.

Several other equities research analysts also recently issued reports on the stock. Rodman & Renshaw initiated coverage on shares of Sana Biotechnology in a research note on Monday, May 11th. They issued a “buy” rating and a $16.00 target price for the company. Wedbush lifted their price target on Sana Biotechnology from $6.00 to $7.00 and gave the stock an “outperform” rating in a report on Tuesday, April 14th. Finally, Weiss Ratings cut Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $9.50.

Sana Biotechnology Stock Performance

Shares of SANA stock opened at $3.15 on Monday. The firm’s fifty day moving average price is $3.27 and its two-hundred day moving average price is $3.61. Sana Biotechnology has a 1 year low of $2.61 and a 1 year high of $6.55. The firm has a market capitalization of $876.61 million, a P/E ratio of -3.39 and a beta of 2.13.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. As a group, equities research analysts forecast that Sana Biotechnology will post -0.59 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Royal Bank of Canada raised its position in shares of Sana Biotechnology by 76.8% in the first quarter. Royal Bank of Canada now owns 12,285 shares of the company’s stock valued at $35,000 after buying an additional 5,338 shares in the last quarter. Mercer Global Advisors Inc. ADV acquired a new stake in Sana Biotechnology during the third quarter worth approximately $36,000. Rockefeller Capital Management L.P. grew its position in Sana Biotechnology by 74.3% during the fourth quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company’s stock worth $39,000 after buying an additional 4,088 shares in the last quarter. Russell Investments Group Ltd. bought a new position in Sana Biotechnology during the 3rd quarter worth $39,000. Finally, LRI Investments LLC bought a new position in Sana Biotechnology during the 4th quarter worth $41,000. 88.23% of the stock is owned by institutional investors.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.